Verismo Therapeutics appoints Laura A. Johnson as chief scientific officer
Dr. Johnson joins Verismo from GlaxoSmithKline Oncology, where she was head of preclinical translational research, and more recently, of clinical biomarkers for cell and gene therapy in the Experimental Medicine Unit.
Prior to joining Verismo, Dr. Johnson was the first Head of Translational Medicine for the Oncology Cell Therapy Research Unit at GlaxoSmithKline Pharma.
During her academic career, Dr. Johnson worked with Prof. Carl June at the University of Pennsylvania, where she built the Solid Tumor Immunotherapy Lab, one of the founding groups in the Penn Center for Cellular Immunotherapies and headed the preclinical translational research into development for clinical trials in glioblastoma (GBM) and other solid tumors.
Earlier in her career, as Assistant Professor at Duke University and cofounder of the Brain Tumor Immunotherapy Program, she developed both syngeneic immune-replete and immune deficient preclinical models to test chimeric antigen receptor (CAR) T-cell therapies in GBM, which became leading in the field, and translated this work into clinical trials at the NIH NCI. ■